Acorda Therapeutics
(NASDAQ:ACOR)
$12.40
0.49[4.11%]
At close: Mar 27
$12.40
0[0.00%]
After Hours: 9:24AM EDT
Q4 2023 Earnings in 3 days from now on Mon Apr 1st, after the market close
Conference call scheduled in 3 days at 16:30 PM Click to view the webcast
Consensus Rating1
Buy
Highest Price Target1
$10.00
Lowest Price Target1
$10.00
Consensus Price Target1
$10.00

Acorda Therapeutics Stock (NASDAQ:ACOR), Analyst Ratings, Price Targets, Predictions

Acorda Therapeutics Inc has a consensus price target of $10, established from looking at the 1 latest analyst ratings. The last 1 analyst ratings were released from HC Wainwright & Co. on June 17, 2021. With an average price target of $10 between HC Wainwright & Co., there's an implied -19.35% downside for Acorda Therapeutics Inc from these 1 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Feb
0
0
0
0
0
Jan
0
0
0
0
0
Dec 23
0
0
0
0
0
Nov 23
0
0
0
0
0
Oct 23
0
0
0
0
0
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Acorda Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
06/17/2021ACORBuy Now
Acorda Therapeutics
$12.40-19.35%HC Wainwright & Co.
Raghuram Selvaraju
UpgradeNeutral → BuyGet Alert

FAQ

Q

What is the target price for Acorda Therapeutics (ACOR)?

A

The latest price target for Acorda Therapeutics (NASDAQ: ACOR) was reported by HC Wainwright & Co. on June 17, 2021. The analyst firm set a price target for $10.00 expecting ACOR to fall to within 12 months (a possible -19.35% downside). 0 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Acorda Therapeutics (ACOR)?

A

The latest analyst rating for Acorda Therapeutics (NASDAQ: ACOR) was provided by HC Wainwright & Co., and Acorda Therapeutics upgraded their buy rating.

Q

When was the last upgrade for Acorda Therapeutics (ACOR)?

A

The last upgrade for Acorda Therapeutics Inc happened on June 17, 2021 when HC Wainwright & Co. raised their price target to $10. HC Wainwright & Co. previously had a neutral for Acorda Therapeutics Inc.

Q

When was the last downgrade for Acorda Therapeutics (ACOR)?

A

There is no last downgrade for Acorda Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Acorda Therapeutics (ACOR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acorda Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acorda Therapeutics was filed on June 17, 2021 so you should expect the next rating to be made available sometime around June 17, 2022.

Q

Is the Analyst Rating Acorda Therapeutics (ACOR) correct?

A

While ratings are subjective and will change, the latest Acorda Therapeutics (ACOR) rating was a upgraded with a price target of $5.00 to $10.00. The current price Acorda Therapeutics (ACOR) is trading at is $12.40, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch